Treatment of Chronic Urticaria During Pregnancy or Lactation

Clinical Scenario

This protocol addresses chronic urticaria in female patients who are currently pregnant or breastfeeding — a population in which treatment selection requires rigorous attention to maternal and fetal or infant safety.

Pregnancy & Lactation — Key Consideration

The same general treatment algorithm for chronic urticaria applies in pregnant and lactating women, but must be followed with caution and only after careful individual risk–benefit assessment. Drugs that are contraindicated or otherwise unsuitable in pregnancy must not be used.

Safety for both the mother and the fetus or infant is the primary constraint shaping every treatment decision in this setting.

Treatment Approach

Treatment is built around a modern 2nd-generation H1-antihistamine, with specific agent preferences established to ensure the highest possible safety margin during pregnancy and lactation — the complete evidence-based selection, including which agents are preferred and why, is available in the full protocol.

Treatment Goals

The aim is continuous complete symptom control: a urticaria activity score (UAS) of 0 and a urticaria control test (UCT) of 16, alongside normalisation of quality of life.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/all.70210

We suggest using the same treatment algorithm with caution both in pregnant and lactating women after risk-benefit assessment.

Drugs contraindicated or not suitable in pregnancy should not be used.

Nevertheless, since the highest safety is mandatory in pregnancy, the suggestion for the use of modern 2nd generation H1-antihistamines is to prefer loratadine with the possible extrapolation to desloratadine and cetirizine with a possible extrapolation to levocetirizine.

1st generation H1-antihistamines should be avoided.

The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life.

View source ↗